Ginkgo Bioworks Holdings (MEX:DNA) Stock Based Compensation: MXN1,468 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:DNA Ginkgo Bioworks Holdings Inc MEX:DNA
54 GF Score
Price MXN170.00
GF Value MXN149.41
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Ginkgo Bioworks Holdings Stock Based Compensation?

Ginkgo Bioworks Holdings MEX:DNA 54 Stock Based Compensation is MXN1,468 Mil as of Mar. 2026. GuruFocus rates MEX:DNA with a GF Score™ of 54/100 and a GF Value™ of MXN149.41 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Ginkgo Bioworks Holdings's Stock Based Compensation for the three months ended in Mar. 2026 was MXN286 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,468 Mil.

Ginkgo Bioworks Holdings Stock Based Compensation Related Terms

Ginkgo Bioworks Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Ginkgo Bioworks Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ginkgo Bioworks Holdings Stock Based Compensation Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 32,945.89 37,639.78 3,902.11 2,343.01 1,468.29

Ginkgo Bioworks Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 355.69 476.23 327.28 378.61 285.87
MEX:DNA
54GF Score
Ginkgo Bioworks Holdings Inc MEX:DNA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ginkgo Bioworks Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,468 Mil.

What does a Stock Based Compensation of MXN1,468 Mil mean?
Ginkgo Bioworks Holdings (MEX:DNA) has a Stock Based Compensation of MXN1,468 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ginkgo Bioworks Holdings and its competitors.
Is Ginkgo Bioworks Holdings' Stock Based Compensation too high?
Ginkgo Bioworks Holdings' current Stock Based Compensation is MXN1,468 Mil. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Stock Based Compensation compare to RZLT and EIKN?
Ginkgo Bioworks Holdings' Stock Based Compensation of MXN1,468 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ginkgo Bioworks Holdings and its competitors. Ginkgo Bioworks Holdings's current Stock Based Compensation is MXN1,468 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (MEX:DNA) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN149.41, compared to a current price of MXN170.00 — trading 13.8% above its estimated fair value. The current Stock Based Compensation is MXN1,468 Mil. Ginkgo Bioworks Holdings' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (MEX:DNA), the current Stock Based Compensation is MXN1,468 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ginkgo Bioworks Holdings (MEX:DNA) Overvalued in 2026?

Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued. The current stock price of MXN170.00 is trading 13.8% above its estimated GF Value™ of MXN149.41. GuruFocus considers Ginkgo Bioworks Holdings to be Modestly Undervalued.

Key valuation signals for MEX:DNA:

  • Stock Based Compensation: MXN1,468 Mil
  • GF Value™: MXN149.41 vs. price of MXN170.00 (13.8% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the MEX:DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ginkgo Bioworks Holdings Business Description

Other Exchanges DNA:USA
Address 27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
54GF Score

Get the complete analysis for MEX:DNA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN170.00
Price
MXN149.41
GF Value